Fifteen drug-free patients with early to midstage Huntington's disease were evaluated with quantitative neurological examinations, scales for functional capacity, computed tomographic (CT) scans, and positron emission tomographic (PET) scans of '*F-2-fluoro-2-deoxyglucose ( '*F-FDG) uptake. All patients had abnormal indices of caudate metabolism on PET scanning, whereas in patients with early disease indices of putamen metabolism and CT measures of caudate atrophy were normal. Indices of caudate metabolism correlated highly with the patients' overall functional capacity ( r = 0.906; p < 0.001) and bradykinesidrigidity (r = -0.692; p < 0.01). Indices of putamen metabolism correlated highly with motor functions: chorea ( r = -0.841; p < 0.01), oculomotor abnormalities (r = -0.849; p < 0.01), and fine motor coordination (r = -0.866, p < 0.01). Indices of thalamic metabolism correlated positively with dystonia (r = 0.559; p < 0.05). The data suggest that PET scanning with "F-FDG is a sensitive measure of brain dysfunction in Huntington's disease and that basal ganglia metabolism is highly correlated with the overall functional capacity of individual patients and with the degree of their motor abnormalities. Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder characterized by progressive cognitive and motor deterioration. The clinical features and natural history of the disease have been carefully evaluated and defined. Early neurological signs include chorea, decreased fine motor coordination, and slowed saccadic eye movements [7, 11, 16, [26] [27] [28] [29] 351. Later signs include dysarthria, rigidity, bradykinesia, and dystonia [7, 11, [26] [27] [28] 351. With progression, the patient's ability to perform activities of daily living declines {4, 5, 26, 27, 291. A number of standardized rating scales have been designed to quantify the motor and functional capacities in this disorder Pathologically, HD is characterized by marked neuronal loss in the caudate nucleus and putamen, with coexistent gliosis and astrocytic proliferation [3, 15, 331. Little or no cortical abnormality has been observed {333. The globus pallidus and thalamus are mildly affected as is the cerebellum {3, 6, 157. These earlier studies investigated patients treated with various pharmacological agents and did not attempt to correlate specific neurological and behavioral findings with brain glucose metabolism. We observed 15 unmedicated HD patients who were evaluated carefully by clinical and neuropsychological testing. We present here our findings on the physiological aspects of the illness. Another report on the results of neuropsychological testing is in preparation [21.
Huntington's disease and that basal ganglia metabolism is highly correlated with the overall functional capacity of individual patients and with the degree of their motor abnormalities. Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder characterized by progressive cognitive and motor deterioration. The clinical features and natural history of the disease have been carefully evaluated and defined. Early neurological signs include chorea, decreased fine motor coordination, and slowed saccadic eye movements [7, 11, 16, [26] [27] [28] [29] 351 . Later signs include dysarthria, rigidity, bradykinesia, and dystonia [7, 11, [26] [27] [28] 351 . With progression, the patient's ability to perform activities of daily living declines {4, 5, 26, 27, 291. A number of standardized rating scales have been designed to quantify the motor and functional capacities in this disorder Pathologically, HD is characterized by marked neuronal loss in the caudate nucleus and putamen, with coexistent gliosis and astrocytic proliferation [3, 15, 331 . Little or no cortical abnormality has been observed {333. The globus pallidus and thalamus are mildly affected as is the cerebellum {3, 6, 157.
With the advent of positron emission tomographic 17,26,27,29,351. (PET) techniques for studying brain metabolism, it has been possible to investigate HD patients at various stages of their illness to determine the relationship between brain metabolism and the neurological features of the disease [12] [13] [14] 231 . Studies with PET have shown a marked reduction of caudate metabolism in patients with early HD who exhibit little or no atrophy as measured by computed tomography (CT) [13}.
These earlier studies investigated patients treated with various pharmacological agents and did not attempt to correlate specific neurological and behavioral findings with brain glucose metabolism. We observed 15 unmedicated HD patients who were evaluated carefully by clinical and neuropsychological testing. We present here our findings on the physiological aspects of the illness. Another report on the results of neuropsychological testing is in preparation [21.
Methods
Fifteen patients with adult-onset HD, as determined by family history and physical examination, were examined at least 1 month after discontinuation of any medications. Over a 2-day period, patients received: (1) a quantitative neurological evaluation conducted by two or more investigators using a previously designed scale 135); (2) an evaluation of functional capacity according to the Shoulson and Fahn scale {29); and (3) neuropsychometric testing (results to be reported separately 12)). In addition, each patient had a CT scan and PET scan using 18F-2-fluoro-2-deoxyglucose ("F-FDG).
The 15 HD patients (ages 25 to 60 years; average ? SEM: 40 * 3 years) were compared with 14 normal controls (ages 25 to 65 years; average 5 SEM: 37 ? 3 years). Patients were in stages I, 11, or 111 of the disease as defined by the Shoulson and Fahn scale, a total functional capacity (TFC) scale that assesses the patient's ability to be gainfully employed, to handle financial and domestic responsib perform activities of daily living, and to be cared for at home 129). It is a 13-point scale with 13 indicating normal and 0 referring to patients who require total care. It is further subdivided into five stages: stage I (TFC 13-11), stage I1 (TFC 10-7), stage I11 (TFC 6-3), stage IV (TFC 2-l), and stage V (TFC 0).
For PET studies, patients had an arterial line placed in the radial artery of one arm and an intravenous line in the other arm. I8F-FDG (5 to 10 mCi) was injected as an intraveous bolus while the patient was in a quiet, dimly lit room with minimal background noise, with eyes blindfolded and ears unplugged. Although sensory deprivation is known to affect glucose metabolism in normal subjects [IS}, these conditions were chosen because they were considered to provide the most reproducible scanning conditions among subjects. Plasma "F-FDG curves were determined for each patient. Repeated 0.5-ml arterial samples were drawn over the first 45 minutes after injection according to the following protocol: injection to 2 minutes, one sample every 5 seconds, then samples at 3,4, 5, 6, 7, 12, 17,22, 37, and 45 minutes.
The scans were obtained on a Cyclotron Corporation PET 4600A Scanner, which is a three-ring (2.2-cm center-tocenter spacing), five-slice, 96-detectorhing tomograph. The spatial resolution is 11 mm in the X-Y plane (within a transaxial slice) and 8.8 mm in the 2 plane (along the central axis of the scanner). Ten transaxial slices separated by approximately 5.5 mm with an orientation parallel to the canthomeatal line were obtained from the base of the cerebellum to the top of the caudate nucleus. An additional five slices separated by 11 mm were acquired to image the next 5 cm of brain. The local glucose metabolic rate (1CMRglc) for each region of brain was calculated according to previously described methods 122, 31) using updated rate constants {Mazziotta JC, personal communication, 1984).
Data from each scan were analyzed by a standard technique as described below. The slice corresponding to the 0-degree Section, No. 8 or No. 9 from the CT atlas of Matsui and Hirano 1171, was analyzed in detad from each patient. Cross-sectional histograms through (I) the caudate nucleus (halfway between the rostral edge of the thalamus and the frontal cortex anterior to the ventricles); (2) the putamen (halfway between the caudate cross-section and the rostral edge of the thalamus); and (3) the middle of the thalamus (Fig 1) . By inspection of the cross-sectional histograms, the maximum glucose metabolic rate over the head of the caudate was observed in all the normal controls and in most of the HD patients. Although caudate metabolism In some of the HD patients was quite low, the location of the shoulder on the cross-sectional histogram could be determined by calculating the second derivative of the curve (Fig 2) . Although this method of determining caudate metabolism cannot correct for alterations in partial volume, it was found to be more reproducible than values obtained from simple, visually guided region-of-interest (ROI) measurements. This method was also considered to be more accurate than the use of standardized ROI programs, which do not correct for the underlying caudate atrophy in HD. Values of caudate, putamen, and thalamus metabolic activity were taken as an average of data from a 1 x 3 pixel ROI (ROI = Z$X,! ICMRglc,,) on a 64 x 64 pixel matrix reconstruction of the PET scan data. Raw data from right and left cortex, caudate, putamen, and thalamus were averaged in 10 patients and 10 controls (Table 1 ). (Data from the first 5 HD patients and first 4 controls were not included in this latter analysis because they were scanned prior to a series of modifications in our scanner that affected absolute but not relative measures of glucose metabolism.) The lack of metabolic change in HD cortex compared with controls suggested that normalization of the values of caudate, putamen, and thalamus to cortex at the same levels was valid for subsequent analyses. Normalization is frequently used in PET studies because it reduces the overall variability of the measures 113, 14, 23) . Absolute measures of metabolism from caudate, putamen, and thalamus were normalized to the peak cortical activity (a 1 x 3 pixel 111 mm2) ROI) determined on the same crosssectional histogram (see Fig 1) . The normalized values will be referred to as indices of metabolism. The ratio of caudate metabolism to putamen metabolism was also calculated for each patient.
In this study, CT scans were evaluated using previously described techniques [I, 25, 30, 32) . Both the frontal horn/ bicaudate diameter ratios (FWCC) and the bicaudate diameter/outer table diameter ratios (CUOT) at the level of the caudate were calculated as depicted in Figure 1 .
PET and CT scan data were obtained and recorded separately from the clinical information. Data from scans and the clinical evaluations were entered into a computer for analysis. The scan measurements were then compared between the controls and HD patients using t tests. The nonparametric clinical data were analyzed and compared to scan data and to each other using Spearman rank correlation coefficients. Parametric scan data were compared to other scan data using Pearson product-moment correlation coefficients. Data analysis was done using the Biomedical Program Statistical Software (Alphaville, CA).
Results
All HD patients had demonstrable PET abnormalities (Figs 2, 3 ). There were 5 stage I patients, 9 stage I1 patients, and 1 stage I11 patient. Measurement of cortical metabolism at the level of the caudate, putamen, and thalamus in the HD patients did not differ significantly from that in controls (see Table 1 ). In HD patients as a population, the caudate and putamen metabolic activity was significantly decreased compared was not significantly different from control values, but when normalized to cortex as in Figure 1 , thalamic/ cortex ratios were significantly higher in HD patients than they were in controls (1.06 t 0.14 standard deviations [SD] versus 0.94 t 0.12 SD; p < 0.02, Student's independent t test). Caudate and putamen indices of metabolism were highly correlated with the TFC of the patient (see Fig   3 , Table 2 ). In the earliest stages of the disease, the caudate index in the HD patients fell just below the lowest index of the control group, and as a group, the stage I patients (TFC = 13-11) had significantly lower caudate indices than did the control group @ < 0.01).
Putamen indices had a strong correlation with TFC, but in stage I patients the putamen indices did not differ significantly from those of the control group. Putamen indices for the stage I1 patients (TFC = 10-7 ) were clearly lower than those of controls (p < 0.01).
The PET measures of caudate and putamen were correlated very highly with each other, but not with the thalamic indices. There was also no correlation between TFC and the thalamic indices of metabolism.
The quantitative neurological measures (chorea, both at rest and during stress), dysdiadochokinesia (evaluated by rapid finger tapping as well as alternating supination and pronation of the hands), abnormalities of saccadic eye movements, bradykinesidrigidity, and dystonia were analyzed in detail ( Table 3) . Motor abnormalities were highly correlated with each other, ex- bValues from each area represent the raw data obtained from 1 X 3 pixel (11 mm2) regions of interest as described in Figure 1 .
'p < 0.001 by two-tailed independent Student's t test.
ICMRglc = local cerebral metabolic rate for glucose; SD = standard deviation.
cept for dystonia which did not relate to abnormal eye movements or bradykinesidrigidity. Abnormalities on the neurological examination were also highly correlated with alterations in basal ganglia metabolism (see Table 2 ). Caudate and putamen indices were correlated significantly with TFC and all motor functions except dystonia. Thalamic indices were correlated only with dystonia. Since PET and CT measures were so highly correlated with each other, multiple linear regression analyses were used to determine the relative contribution of the metabolic and CT data to the functional and neurological features of the patient. The caudate index of metabolism accounted for 85.3% of the variation in TFC (F[1,12) = 69.6), with the FWCC ratio accounting for an additional 4.0% of the variability (F[2,11) = 47.6) and the caudate/putamen ratio accounting for another 3.0% (F[3,10) = 42.1). For neurological measures, the putamen index accounted for most of the variability in chorea, dysdiadochokinesia, and abnormal eye movements; the caudate index accounted for the variability of bradykinesidrigidity; the thalamus and putamen indices together accounted for the variability of dystonia.
CT scan measures of the CC/OT ratio correlated with TFC, oculomotor abnormalities, dysdiadochokinesia, and resting chorea. CC/OT ratios were significantly correlated with PET caudate and putamen indices ( Table 4 ). The CT scan measure of the FWCC ratio was not significantly correlated with TFC or any of the neurological signs, but was correlated with caudate and thalamic metabolism. 
Discussion
Our data indicate that basal ganglia metabolism is clearly abnormal in HD and that the degree of metabolic abnormality is correlated both with the patients' overall TFC as well as with their neurological signs and symptoms. The TFC scale used in this study has been validated in prior studies of CT measures [30J and in studies of the clinical progression of the disease [26, 27, 351 . This scale seems to be very sensitive to measures of early progression in the illness. Our study confirms previous CT studies of HD 125, 30, 321 and provides evidence that metabolic measures in caudate are even more sensitive in early disease than are CT measures. Caudate metabolism is particularly sensitive to functional decline since even patients with the earliest forms of the disease had caudate metabolism below that of the lowest normal subject examined. In these patients with early HD, CT measures were normal. The presence of a relationship between functional capacity and caudate metabolism is further established by the strong correlation between TFC and verbal learning and memory, cognitive efficiency, and years after diagnosis. Also, there is a strong correlation between caudate metabolism and learning and memory
127.
The fact that in early HD caudate metabolism is affected more dramatically than is putamen metabolism reinforces the pathological information on patients with early disease that the disorder begins in the caudate nucleus (specifically the dorsal medial areas of caudate) and then progresses to the putamen 1337.
Putamen metabolism is not as sensitive since there was overlap between stage I patients and the control group in this measure. That caudate and putamen metabolism were only mildly reduced in patients with early disease suggests that either the symptoms of HD begin soon after the onset of neuronal damage or that compensatory properties maintain or even increase metabolic activity in the remaining basal ganglia neurons.
Caudate metabolism was not as significantly cor- The high correlation of putamen metabolism with motor abnormalities may reflect the fact that the putamen receives input from sensory and motor cortex C81. Multiple regression analyses further support this conclusion since putamen indices explained most of the variability in the motor features except for dystonia and bradykinesidrigidity. Thus, dysfunction of putamen neurons would likely lead to poor motor coordination.
Thalamic activity was correlated with dystonia, and it is of interest that metabolic activity in this area was increased in the HD patients as a group compared with controls. Neuroanatomical and neurochemical information suggests that the caudate and putamen output cells project to the medial and lateral globus pallidus and substantia nigra pars reticulata IS}. These projections are primarily inhibitory and y-aminobutyric acid-ergic (GABAergic) 120, 341. The medial globus pallidus and substantia nigra pars reticulata neurons are also inhibitory and GABAergic, and project to the thalamus [20, 341 . Thus the increased thalamic metabolism in HD patients may represent a disinhibition of pallidothalamic and nigrothalamic pathways. Our data would suggest that excessive input to the thalamus from the globus pallidus and substantia nigra pars reticulata may contribute to dystonic motor abnormalities. We plan a future study of rigid and dystonic juvenile patients.
There have been other studies of PET scanning in HD [12-14, 19, 21, 231 . As previously described, we found a significant decrease in the glucose metabolic rate in the basal ganglia of patients with early disease while there was little or no caudate atrophy observed on CT scans. However, unlike previous authors 112, 141 , we found less difference between the glucose metabolic rate of our patients with early disease and that of controls. In addition, we observed strong direct correlations between metabolic indices and the degree of functional or motor abnormalities in the patients.
Others have studied at-risk persons and found altered metabolism in about one half of the subjects 112, 131. Some of these patients have gone on to develop HD 112). We are currently studying 40 at-risk persons prospectively but have found only minimal caudate changes to date. The studies in at-risk persons will help define further the relationship between the earliest metabolic changes and motor and cognitive decline.
In summary, PET measures of basal ganglia metabolism have reinforced our knowledge of basal ganglia anatomy, physiology, and pathology and suggest that such measures will be useful indicators of functional and clinical decline in HD patients. If subsequent atrisk studies confirm that there are significant metabolic changes before the onset of symptoms, then prophylactic therapy in conjunction with PET scanning may provide a useful measure of therapeutic agents. Such measures will be particularly important since the new data describing a DNA marker linked to the HD gene will soon allow the diagnosis of HD in presymptomatic patients [9, lo] .
